Archives of Gastroenterology Research

Case Report Open Access

Neurofibromatosis Type 1 and Crohn’s Disease Association: Case Report

Aamir AlShahrabally , D Coghlan , S Quinn

We described a 15-year-old- a boy who presented with neurofibromatosis type 1 and Crohn’s disease. Neurofibromatosis 1 (NF1) is the most common form of NF, affecting 1 in 3000 individuals. Crohn’s disease is one of the inflammatory bowel diseases. Its incidence is significantly rising in Ireland. Concomitant association of NF1 and Crohn’s disease is a rare finding. This is the first case reported in the paediatric population.

Review Article Open Access

Exploring the Use of Point of Care Ultrasound in Screening for Non-Alcoholic Fatty Liver Disease: A Systematic Literature Review and Meta-Analysis

Oscar L. Hernandez , Zoilo Karim Suarez Yeb , Talwinder Nagi , Muhammad Adnan Haider , Charles Vallejo , Fatima Ahson

Non-alcoholic fatty liver disease (NAFLD) is a major cause of cirrhosis and liver failure globally. Despite its broad impact, screening recommendations for NAFLD remain varied based between gastrointestinal societies. Point of care ultrasound (POCUS) has emerged as a new form of screening and diagnosing intrabdominal pathologies including NAFLD. We aimed to estimate the effectiveness of POCUS in screening for NAFLD

Clinical Image Open Access

A Rare Endoscopic Finding: Gastric Diverticulum

Yi-Xue Zhou , Qiao-Yun Tong , Wei Liu

A 40-year-old man received upper gastrointestinal endoscopic scan during a health check-up. There was no history suggestive of Helicobacter pylori eradication, reflux esophagitis, peptic ulcer disease and upper abdominal surgery. Endoscopy revealed a wide-mouthed diverticulum of the size of 1.5 × 2 cm between the fundus and greater curvature of the stomach (Figure 1).

Review Article Open Access

Preclinical Promise and Clinical Challenges for Innovative Therapies Targeting Liver Fibrogenesis

Tamer A. Addissouky , Majeed M. A. Ali , Ibrahim El Tantawy El Sayed , Yuliang Wang , Ayman El Baz , Naglaa Elarabany , Ahmed A. Khalil

Liver fibrosis resulting from chronic liver injury can progress to cirrhosis and liver failure. Current treatments are limited, creating an urgent need for novel antifibrotic therapies. Multiple emerging approaches have shown preclinical promise in inhibiting liver fibrogenesis or stimulating regeneration, including artificial liver support, stem cell therapy, cell/gene therapy, nanomedicines, immunotherapy, and herbal medicines.

Review Article Open Access

Advancements in Drug Delivery Systems for Natural Compounds Targeting Metabolic Disorders Associated with Inflammation

Roberto Sam , Sel Neal

The global incidence of metabolic disorders is on the rise, posing a significant challenge to public health. With remarkable advancements in diagnostic tools and clinical procedures, our understanding of the etiology and underlying pathophysiology of these disorders has expanded considerably. Furthermore, the utilization of in vitro and in vivo experimental models, preceding clinical investigations, has catalyzed numerous breakthroughs in biomedicine, particularly in the identification and development of potential drug candidates for the management of metabolic disorders.